CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program
TORONTO, ON / ACCESSWIRE / July 26, 2023 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, United Kingdom, a global information sharing platform & multi-disciplinary members community.
About: Global Health & Pharma
Global Health & Pharma Magazine (GHP) was initially launched to act as an information-sharing platform for those in the healthcare and pharmaceutical industries. Though it maintains this founding cornerstone, the magazine itself, with a circulation of 110,000 globally, has expanded in scope to magnify the work of those that are setting the pace and looking to change their respective sectors for the better. In the years since our establishment, we have grown to 1,340,669 page views in the last 12 months averaging at 111,722 page views per month we can see our magazine is loved by many. The unique users average at 27,063 per month and we can’t thank our readers enough for the amazing support they give us to bring this content to you. Utilizing this reach, we aim to provide support and help showcase the latest developments, most promising innovations, and leading companies across the medical and health industries. This is our core mission, and we endeavor to continue to offer an unbiased lens on what is happening for all companies within and without the sphere.
For more information on Global Health & Pharma, visit https://www.ghp-news.com/about-us/.
About: CanaQuest Medical Corp
CanaQuest Medical, a clinical-stage, life sciences company, is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder “PTSD”, including addiction. CanaQuest has created a game-changing Master Formulation derived from cannabidiol “CBD” + IP formula. It has a Drug Candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy. An OTC version of the Master Formulation, branded as Mentanine®, is available for sale via CanaQuest Store in the US without health claims. Pre-clinical trial results and Clinical Studies have demonstrated beneficial effects on several mental and neurological conditions. Its non-psychoactive properties provide a safe and effective alternative to traditional treatments with little to no side effects.
On April 25, 2023, CanaQuest announced the signing of a Master Service Agreement with Neeka Health, a leader in digital health technologies and in conducting cost-efficient, decentralized clinical trials, that will encompass multiple clinical studies to evaluate the efficacy of Mentanine® on targeted populations struggling with transitional issues.
For more information, visit www.canaquest.com.
CANAQUEST CONTACT:
Paul Ramsay, President
paul@canaquest.com
SOURCE: CanaQuest Medical Corp.
View source version on accesswire.com:
https://www.accesswire.com/770412/CanaQuest-Awarded-Best-Global-Medical-Cannabinoid-Development-Company-2023-by-UK-based-Global-Health-Pharma-for-their-8th-Annual-Healthcare-and-Pharmaceutical-Program
